Deals & funding29 Sep 2026 · Mon
SUNPHARMASun Pharmaceutical Industries
Sun Pharma licenses cholesterol drug lerodalcibep for markets outside the US and China
Sun Pharma signed an exclusive licensing deal with LIB Therapeutics to sell and make the once-monthly cholesterol injection lerodalcibep outside the US and China.
Price, Monday's close₹1,838.00▼ 0.77%
Last 5 days
52-week low ₹1,580.0052-week high ₹2,046.90
- Sector
- Pharma
What happened
- Sun Pharmaceutical Industries signed an exclusive licensing agreement with LIB Therapeutics for lerodalcibep, a once-monthly injection that lowers LDL cholesterol.
- Sun Pharma gets the rights to sell and manufacture the drug in all markets except the United States and China.
- LIB Therapeutics will receive an upfront payment, milestone payments and royalties on sales. The amounts were not disclosed.
Why it matters
The drug was approved in the European Union on 21 September 2026 and is already sold in the US. The companies put the market for this class of drug (PCSK9 inhibitors) outside the US and China at about $3.7 billion, of which Europe is about $2.9 billion, citing IQVIA data.
Key facts
- Partner
- LIB Therapeutics
- Territory
- Worldwide except the US and China
- EU approval
- 21 September 2026
Read the source
This is a summary of public news about Sun Pharmaceutical Industries, for information only. It is not a recommendation to buy, sell or hold SUNPHARMA.
Sun Pharmaceutical Industries in the news before
- 2 NOV 2026 · EVENING · RESULTSSun Pharma's Q2 profit falls 36% to ₹1,989 crore after a ₹1,269 crore one-time loss
- 21 OCT 2026 · REGULATORYSun Pharma's Unloxcyt gets NCCN 2A preferred status for locally advanced skin cancer
- 14 OCT 2026 · EVENING · CORPORATE ACTIONSSun Pharma's board approves up to ₹10,000 crore of debentures; a director resigns